From Obesity Drug Design to System Design: Pairing GLP-1s With Metabolic AI Digital Twins
This month, Viking Therapeutics says it has finished enrolling the Phase 3 VANQUISH-1 trial for its injectable obesity drug VK2735, plans to move an oral VK2735 into Phase 3 and intends to file an IND for a new amylin-agonist obesity program.
WIRED also profiles Twin Health, a Silicon